Improvement of level MDA and SOD Using of Ganoderma Lucidum as Adjunctive Treatment for Statin Based Therapy in High Risk Patient Based on Framingham Score
Abstract
It is well known from previous research on the importance of antioxidants to inhibit the progression of coronary heart disease in high-risk patients based on framingham scores. Statins are routinely administered in high-risk patients based on the Dyslipidemia 2016 ESC guidelines but the effects of adding Ganoderma are known to have antioxidant effects, in patients who have received statins. This study aims to assess the effect of antioxidants through measurement of SOD and MDA in patients given a combination of Ganoderma lucidum with statins.Method: A total of 24 patients with high-risk patients based on the Framingham score > 20% were selected as sample of study. Patients with respondents who had never received statin therapy or ACEi or ARB or CCB or beta blocker, or did not routinely consume the drug for 2 weeks were excluded from this study. The addition of Ganoderma lucidum dose of 3x250 mg was added to statins as the first group and Ganoderma lucidum dose of 3x250 mg was added to the Statin combination of Angiotensin Converting Enzym inhibitors (ACE inhibitors) or Angiotensin Receptor Blockers (ARB) and or Calcium Channel Blockers (CCB) and or Beta blockers as second group for 90 days. SOD and MDA levels were measured before and after the administration of Ganoderma Lucidum with the ELISA method.Result: After the administration of Ganoderma Lucidum with standard therapy, there was a decrease in MDA levels and an increase in SOD levels after 90 days in two groups. Conclusion: The addition of Ganoderma Lucidum to standard therapy can reduce oxidant levels in high-risk patients based on framingham scores.
Keyword: Superoxyde-dismutase, Malondyaldehide, Oxidative Stress, Antioxidant, Ganoderma Lucidum, Statin
Downloads
References
Global Epidemic of Cardiovascular Disease: Meeting
the Challenges in Developing C. The National
Academies Collection: Reports funded by National
Institutes of Health. In: Fuster V, Kelly BB, editors.
Promoting Cardiovascular Health in the Developing
World: A Critical Challenge to Achieve Global
Health. Washington (DC): National Academies
Press (US) National Academy of Sciences.; 2010.
2. Delima LM, Hadi Siswoyo. Prevalensi dan faktor
determinan penyakit jantung di Indonesia Bul Penelit
Kesehat. 2009;37:: 142 - 15.
3. Gui T, Shimokado A, Sun Y, Akasaka T, Muragaki
Y. Diverse roles of macrophages in atherosclerosis:
from inflammatory biology to biomarker discovery.
Mediators of inflammation. 2012;2012:693083
4. Chen SN, Nan FH, Chen S, Wu JF, Lu CL, Soni
MG. Safety assessment of mushroom beta-glucan:
subchronic toxicity in rodents and mutagenicity
studies. Food and chemical toxicology : an international
journal published for the British Industrial Biological
Research Association. 2011;49(11):2890-8.
5. Wang XC, Xi RJ, Li Y, Wang DM, Yao YJ. The
species identity of the widely cultivated Ganoderma,
'G. lucidum' (Ling-zhi), in China. PloS one.
2012;7(7):e40857
6. Shirley R, Ord ENJ, Work LM. Oxidative Stress
and the Use of Antioxidants in Stroke. Antioxidants.
2014;3(3):472-501.
7. Pashkow FJ. Oxidative Stress and Inflammation
in Heart Disease: Do Antioxidants Have a Role in
Treatment and/or Prevention? International journal
of inflammation. 2011;2011:514623.
8. Smina TP, Mathew J, Janardhanan KK, Devasagayam
TP. Antioxidant activity and toxicity profile of
total triterpenes isolated from Ganoderma lucidum
(Fr.) P. Karst occurring in South India. Environmental
toxicology and pharmacology. 2011;32(3):438-
46.
9. Smina TP, Mathew J, Janardhanan KK, Devasagayam
TP. Antioxidant activity and toxicity profile of
total triterpenes isolated from Ganoderma lucidum
(Fr.) P. Karst occurring in South India. Environmental
toxicology and pharmacology. 2011;32(3):438-
46.
10. Pan D, Zhang D, Wu J, Chen C, Xu Z, Yang H, et
al. Antidiabetic, antihyperlipidemic and antioxidant
activities of a novel proteoglycan from ganoderma
lucidum fruiting bodies on db/db mice and the possible
mechanism. PloS one. 2013;8(7):e68332.
11. Lee J LP. Lipoproteins and the Endothelium: Past,
Present and Future Hellenic journal of cardiology
: HJC = Hellenike kardiologike epitheorese.
206;47:158-9.
12. Casieri V, Matteucci M, Cavallini, et.al. Long term
intake of pasta containing barley (1-3) beta-D-glucan
increases neovascularization-mediated cardioprotection
through endothelial upregulation of
vascular endothelial growth factor and parkin. Scientific
Reports, 2017:13424
13. Taylor F, Huffman MD, Macedo AF, et al. Statins
for the primary prevention of cardiovascular disease.
Cochrane Database Syst Rev 2013; (1): CD004816.
14. Mihaylova B, Emberson J, Blackwell L, et al. The
effects of lowering LDL cholesterol with statin therapy
in people at low risk of vascular disease: meta-
analysis of individual data from 27 randomised
trials. Lancet 2012; 380(9841): 581–590.
15. Taylor F, Huffman MD, Macedo A, Moore THM,
Burke M, Davey Smith G, Ward K, Ebrahim S.
Statins for the primary prevention of cardiovascular
disease. 31 January 2013
16. Wilck N and Ludwig A. Targeting the ubiquitin-
proteasome system in atherosclerosis: Status
quo, Challenges and perspectives. Antioxidants &
redox signaling volume 21,number 17,2014
17. Alexios S. Antonopoulos, Marios Margaritis, Regent
Lee, Keith Channon, and Charalambos Antoniades.
Statins as Anti-Inflammatory Agents in Atherogenesis:
Molecular Mechanisms and Lessons from the
Recent Clinical Trials. Current Pharmaceutical Design,
2012, 18, 1519-153
18. Wilck N and Ludwig A. Targeting the ubiquitin-
proteasome system in atherosclerosis: Status
quo, Challenges and perspectives. Antioxidants &
redox signaling volume 21,number 17,2014
19. Alexios S. Antonopoulos, Marios Margaritis, Regent
Lee, Keith Channon, and Charalambos Antoniades.
Statins as Anti-Inflammatory Agents in Atherogenesis:
Molecular Mechanisms and Lessons from the
Recent Clinical Trials. Current Pharmaceutical Design,
2012, 18, 1519-153
20. Vasankari T, Ahotupa M, Viikari J, Nuotio I,
Strandberg T, Vanhanen H, Gylling H, Miettinen
T, Tikkanen MJ. Effect of 12-month statin therapy
on antioxidant potential of LDL and serum antioxidant
vitamin concentrations. Ann Med 2004;36:
618–622.
PDF downloads: 2716
Copyright (c) 2019 Indonesian Journal of Cardiology
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
